Astrazeneca PLC Company Profile (NYSE:AZN)

About Astrazeneca PLC

Astrazeneca PLC logoAstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. The Company has its operations in over 100 countries. The Company's pipeline includes over 150 projects of which approximately 125 are in the clinical phase of development. The Company is developing a Toll-like receptor 9 (TLR-9) receptor agonist aimed at producing long-term benefit in asthma by addressing imbalances in the immune system. AstraZeneca offers various products, including Accolate, Rhinocort, Bricanyl Turbuhaler, Rhinocort, Symbicort pMDI, Crestor, Seloken/Toprol-XL, Brilinta/Brilique (ticagrelor), Bydureon, Xigduo XR, Kombiglyze XR and metformin XR, among others.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: N/A
  • Exchange: NYSE
  • Symbol: AZN
  • CUSIP:
Key Metrics:
  • Previous Close: $33.23
  • 50 Day Moving Average: $32.54
  • 200 Day Moving Average: $29.95
  • Trailing P/E Ratio: 37.77
  • Foreward P/E Ratio: 16.86
  • P/E Growth: -13.45
  • Market Cap: $83.62B
  • Outstanding Shares: 2,530,000,000
  • Beta: 0.73
Additional Links:
Companies Related to Astrazeneca PLC:

Analyst Ratings

Consensus Ratings for Astrazeneca PLC (NYSE:AZN) (?)
Ratings Breakdown: 2 Sell Ratings, 9 Hold Ratings, 8 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Hold (Score: 2.40)
Consensus Price Target: $36.40 (10.14% upside)

Analysts' Ratings History for Astrazeneca PLC (NYSE:AZN)
DateFirmActionRatingPrice TargetDetails
8/26/2016Beaufort SecuritiesReiterated RatingHoldView Rating Details
8/10/2016Shore CapitalReiterated RatingHoldView Rating Details
8/10/2016Citigroup Inc.Reiterated RatingBuyView Rating Details
8/8/2016JPMorgan Chase & Co.Reiterated RatingNeutralView Rating Details
8/8/2016Cantor FitzgeraldReiterated RatingBuyView Rating Details
7/18/2016Bank of America Corp.Reiterated RatingBuy$36.65View Rating Details
7/12/2016ArgusInitiated CoverageHoldView Rating Details
6/27/2016Deutsche Bank AGReiterated RatingBuyView Rating Details
6/16/2016Leerink SwannReiterated RatingHold$34.00View Rating Details
6/6/2016Jefferies GroupReiterated RatingHoldView Rating Details
5/27/2016Goldman Sachs Group Inc.Reiterated RatingSellView Rating Details
2/28/2016Drexel HamiltonInitiated CoverageBuyView Rating Details
2/8/2016HSBCDowngradeBuy -> HoldView Rating Details
2/5/2016Sanford C. BernsteinLower Price Target$34.00 -> $32.00View Rating Details
1/26/2016Oddo SecuritiesUpgradeNeutral -> Top PickView Rating Details
1/19/2016Barclays PLCUpgradeUnderweight -> Equal Weight$44.00 -> $50.00View Rating Details
1/13/2016Credit Suisse Group AGReiterated RatingUnderperformView Rating Details
12/30/2015Morgan StanleyReiterated RatingBuyView Rating Details
11/30/2015BNP ParibasReiterated RatingOutperformView Rating Details
11/2/2015Nordea Equity ResearchDowngradeBuy -> HoldView Rating Details
9/18/2015Bryan, Garnier & CoUpgradeNeutral -> BuyView Rating Details
7/31/2015S&P Equity ResearchUpgradeBuy$38.00View Rating Details
7/31/2015SwedbankUpgradeNeutral -> BuyView Rating Details
7/2/2015Berenberg BankUpgradeHold -> BuyView Rating Details
6/2/2015Kepler Capital MarketsReiterated RatingReduceView Rating Details
4/16/2015Liberum CapitalReiterated RatingBuyView Rating Details
4/15/2015Societe GeneraleInitiated CoverageBuyView Rating Details
2/6/2015Panmure GordonReiterated RatingBuyView Rating Details
2/6/2015DanskeDowngradeSellView Rating Details
2/3/2015SEB Equity ResearchUpgradeHold -> BuyView Rating Details
(Data available from 8/29/2014 forward)


Earnings History for Astrazeneca PLC (NYSE:AZN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/28/2016Q216$0.76$0.83$5.56 billion$5.60 billionViewListenView Earnings Details
4/29/2016Q1$0.60$0.51$5.96 billion$6.12 billionViewListenView Earnings Details
2/4/2016Q415$0.88$0.94$6.27 billion$6.40 billionViewN/AView Earnings Details
11/5/2015Q315$0.51$1.03$5.90 billion$5.85 billionViewN/AView Earnings Details
7/30/2015Q2$1.08$1.21$6.02 billion$5.84 billionViewListenView Earnings Details
4/24/2015Q1$1.07$1.08$5.87 billion$6.06 billionViewN/AView Earnings Details
2/5/2015Q314$0.85$0.76$6.68 billion$6.68 billionViewN/AView Earnings Details
11/6/2014Q3$1.04$1.05$6.44 billion$6.54 billionViewN/AView Earnings Details
7/31/2014Q214$1.09$1.30$6.24 billion$6.45 billionViewN/AView Earnings Details
4/24/2014Q114$1.23$1.17$6.32 billion$6.42 billionViewN/AView Earnings Details
2/6/2014Q413$1.22$1.23$6.91 billion$3.84 billionViewN/AView Earnings Details
10/31/2013Q313$1.27$1.21$6.45 billion$6.25 billionViewN/AView Earnings Details
8/1/2013Q213$1.16$1.20$6.24 billion$6.23 billionViewN/AView Earnings Details
4/25/2013$1.36$1.41$6.54 billion$6.39 billionViewN/AView Earnings Details
1/31/2013Q412$1.37$1.56$7.17 billion$7.28 billionViewN/AView Earnings Details
10/25/2012$1.44$1.51ViewN/AView Earnings Details
7/26/2012$1.38$1.53ViewN/AView Earnings Details
4/26/2012$1.73$1.81ViewN/AView Earnings Details
2/2/2012$1.57$1.61ViewN/AView Earnings Details
10/27/2011$1.64$1.71ViewN/AView Earnings Details
7/28/2011$1.74$1.53ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Astrazeneca PLC (NYSE:AZN)
Current Year EPS Consensus Estimate: $2.07 EPS
Next Year EPS Consensus Estimate: $1.96 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162$0.53$1.01$0.77
Q2 20162$0.40$0.45$0.43
Q3 20161$0.55$0.55$0.55
Q4 20161$0.58$0.58$0.58
(Data provided by Zacks Investment Research)


Current Dividend Information for Astrazeneca PLC (NYSE:AZN)
Annual Dividend:$1.37
Dividend Yield:4.15%
Payout Ratio:78.29% (Based on Trailing 12 Months of Earnings)
66.18% (Based on Current Year Consensus EPS Estimate)
69.90% (Based on Next Year Consensus EPS Estimate)
Dividend Growth:-6.60% (3 Year Average)

Dividend History for Astrazeneca PLC (NYSE:AZN)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Astrazeneca PLC (NYSE:AZN)
No insider trades for this company have been tracked by


Latest Headlines for Astrazeneca PLC (NYSE:AZN)
DateHeadline logoDow 30 Stock Roundup: Pfizer's Big Buy, Boeing's Big Win (NYSE:AZN) - August 26 at 11:49 AM logoAZN October 7th Options Begin Trading (NYSE:AZN) - August 25 at 3:46 PM logoPfizer Inks a $1.6 Billion Deal with AstraZeneca (NYSE:AZN) - August 25 at 3:46 PM logoDrug Makers Stocks under Review -- Bristol-Myers Squibb, AstraZeneca, Eli Lilly, and GlaxoSmithKline (NYSE:AZN) - August 25 at 8:33 AM
News IconAstraZeneca PLC (NYSE:AZN) from Drug Manufacturers – Major – Todays Top Gains (NYSE:AZN) - August 25 at 8:33 AM logoMedImmune won't be impacted by AstraZeneca sale of antibiotic business to Pfizer (NYSE:AZN) - August 25 at 8:33 AM logoAstraZeneca and Its Oncology Segment’s Growth in 2Q16 (NYSE:AZN) - August 25 at 8:33 AM
News IconThe Key Numbers To Watch From AstraZeneca PLC (NYSE:AZN)'s Earnings - The Voice Registrar (NYSE:AZN) - August 24 at 3:43 PM logoEuropean Markets Mixed as Volatility Hits 17-Month Low (NYSE:AZN) - August 24 at 11:58 AM
News IconEli Lilly, AstraZeneca Get Fast Track Designation for Alzheimer's Drug (NYSE:AZN) - August 22 at 3:45 PM logoJuly FOMC Minutes: Brexit Impact on US Not as Bad as Expected (NYSE:AZN) - August 22 at 3:45 PM logoStocks Struggle for Direction as Jackson Hole Conference Looms (NYSE:AZN) - August 22 at 3:45 PM
News IconDrug Manufacturers – Major: AstraZeneca PLC (NYSE:AZN) Position of the day (NYSE:AZN) - August 20 at 8:44 AM logoAstraZeneca plc (ADR) (AZN) Making New Innovation for COPD Patients - TCC (NYSE:AZN) - August 18 at 3:52 PM
News IconLarge Cap Drug Manufacturers – Major: AstraZeneca PLC (NYSE:AZN) (NYSE:AZN) - August 17 at 9:09 PM
News IconAstraZeneca plc (ADR) (AZN) Making New Innovation for COPD Sufferers (NYSE:AZN) - August 17 at 9:09 PM
News IconTop Gainers of the Day: AstraZeneca PLC (NYSE:AZN) from Drug Manufacturers – Major (NYSE:AZN) - August 16 at 9:00 PM
News IconAstraZeneca share price: Pharmco wraps up deal with LEO Pharma (NYSE:AZN) - August 16 at 12:24 PM logoAstraZeneca : Completes Licensing Pact with LEO Pharma for Tralokinumab (NYSE:AZN) - August 16 at 12:24 PM logoWill AstraZeneca plc (ADR) (ANZ) Cope with the Future Challenges? (NYSE:AZN) - August 16 at 12:24 PM logoAstraZeneca plc (ADR) (AZN) Got Breakthrough In The UK Market (NYSE:AZN) - August 15 at 10:55 AM logoWill AstraZeneca plc (AZN) Survive Crestor Loss? (NYSE:AZN) - August 13 at 11:53 AM logoAstraZeneca Plc (NYSE:AZN) Brilinta Wins UK Cost Approval For Long Term Use (NYSE:AZN) - August 12 at 12:18 PM
News IconAstraZeneca Increases Stake in U.S. Biotech Firm Moderna Therapeutics (NYSE:AZN) - August 10 at 4:06 PM
News IconRevenue Estimates Spotlight: AstraZeneca PLC (NYSE:AZN) - News Oracle (NYSE:AZN) - August 10 at 7:29 AM logoAstrazeneca PLC (AZN) Ex-Dividend Date Scheduled for August 10, 2016 - Nasdaq (NYSE:AZN) - August 10 at 7:29 AM logo[$$] Inovio Pharma May Be Burning Too Hot (NYSE:AZN) - August 10 at 7:29 AM logoBristol Myers Shares Sink as Lung-Cancer Drug Misses Goal (NYSE:AZN) - August 5 at 9:06 PM
News IconLeading stocks in today’s market: AstraZeneca PLC (NYSE:AZN) (NYSE:AZN) - August 5 at 9:06 PM logoBristol-Myers: All Is Not Lost (NYSE:AZN) - August 5 at 3:44 PM logoBristol-Myers Squibb's Loss Is "A Big Win" For Merck (NYSE:AZN) - August 5 at 12:08 PM logoETF’s with exposure to AstraZeneca Plc : August 4, 2016 (NYSE:AZN) - August 4 at 3:48 PM logoAstraZeneca Plc :AZN-US: Earnings Analysis: Q2, 2016 By the Numbers : August 3, 2016 (NYSE:AZN) - August 3 at 12:18 PM logoIncreasing Risk of CVDs to Help Salvage the Global Hypercholesterolemia Drugs Market Through 2020, Says Technavio (NYSE:AZN) - August 3 at 12:18 PM logoExane BNP Paribas disclosed (LON:AZN) AstraZeneca PLC, hiking its target price to 5,300GBX earlier today (NYSE:AZN) - August 2 at 8:31 AM logoHutchison China MediTech Limited (“Chi-Med”) Reports Interim Results for the Six Months Ended June 30, 2016, Provides 2016 Financial Guidance and Updates Shareholders on Key Clinical Programs (NYSE:AZN) - August 2 at 8:31 AM logoAstraZeneca PLC (LON:AZN) price target held steady at 5,800GBX as covered today by Deutsche Bank (NYSE:AZN) - August 1 at 8:37 AM logoChi-Med and AstraZeneca Amend Co-development Agreement to Accelerate Savolitinib Global Development Program (NYSE:AZN) - August 1 at 3:32 AM logoTech vs biotech: Is AstraZeneca plc or Apple Inc. the better buy? (NYSE:AZN) - August 1 at 2:05 AM logoAstraZeneca Group plc 2016 Q2 - Results - Earnings Call Slides (NYSE:AZN) - July 31 at 3:39 PM
News IconAnalyst Recommendations Review: AstraZeneca PLC (NYSE:AZN) - News Oracle (NYSE:AZN) - July 28 at 4:46 PM logoAstraZeneca (AZN) Stock Up After Q2 Earnings, Revenue Beat (NYSE:AZN) - July 28 at 2:13 PM logoNotable Analysts Recommendation to Monitor: Astrazeneca PLC ... - Street Updates (NYSE:AZN) - July 27 at 12:14 PM logoBristol-Myers Squibb’s 2Q16 Estimates: Other Segments (NYSE:AZN) - July 27 at 11:05 AM
News IconA look at a High Market Cap Stock: AstraZeneca PLC, AZN – The ... - The Daily Leicester (NYSE:AZN) - July 26 at 9:43 PM logoAstrazeneca : 2Q 2016 -- Forecast (NYSE:AZN) - July 25 at 4:16 PM logoLatest Analysts Score of Stocks: Astrazeneca PLC (NYSE:AZN) , Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) - Street Updates (NYSE:AZN) - July 25 at 8:31 AM logo[$$] New drugs aim to kill cancer cells by destabilising their DNA (NYSE:AZN) - July 24 at 11:48 AM
News IconAre Analysts Bearish AstraZeneca plc (LON:AZN) After Last Week? - Consumer Eagle (NYSE:AZN) - July 23 at 3:42 PM logoEuropean Stock Markets Mixed After Signs of Brexit Damage (NYSE:AZN) - July 22 at 12:58 PM


Astrazeneca PLC (NYSE:AZN) Chart for Monday, August, 29, 2016

Last Updated on 8/29/2016 by Staff